OCA, an FXR agonist, regulates the expression of transcription factors that reduce BA synthesis and liver steatosis.202 In a clinical phase 2 trial (NCT01265498), OCA improved the histological features of NASH. Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.